CLINICAL TRIALS PROFILE FOR DESOGESTREL; ETHINYL ESTRADIOL
✉ Email this page to a colleague
All Clinical Trials for desogestrel; ethinyl estradiol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00204438 ↗ | Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle | Completed | Canadian Institutes of Health Research (CIHR) | N/A | 2002-02-01 | We hypothesize that administration of OCs at varying follicular diameters will provide an appropriate model for the study of follicular atresia in women. Clinically, we hypothesize that the administration on OCs at different stages of the follicular phase will result in markedly different patterns of follicular development and/or atresia. |
| NCT00204438 ↗ | Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle | Completed | University of Saskatchewan | N/A | 2002-02-01 | We hypothesize that administration of OCs at varying follicular diameters will provide an appropriate model for the study of follicular atresia in women. Clinically, we hypothesize that the administration on OCs at different stages of the follicular phase will result in markedly different patterns of follicular development and/or atresia. |
| NCT00439972 ↗ | Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity | Unknown status | Ortho-McNeil Pharmaceutical | Phase 2 | 2007-02-01 | The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status. |
| NCT00439972 ↗ | Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity | Unknown status | University of Washington | Phase 2 | 2007-02-01 | The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status. |
| NCT00612508 ↗ | Hormonal Contraception and Vaginal Health | Completed | Oregon Clinical and Translational Research Institute | N/A | 2007-05-01 | The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring). |
| NCT00612508 ↗ | Hormonal Contraception and Vaginal Health | Completed | Oregon Health and Science University | N/A | 2007-05-01 | The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring). |
| NCT01256619 ↗ | Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health | Unknown status | Tehran University of Medical Sciences | Phase 2 | 2010-09-01 | The desogestrel (150 mg) in combination with ethinyl estradiol (EE, 30 mg) is known as Marvelon in European countries. Previous studies revealed that the Marvelon is good and safe for women. As a study from Thailand showed that the Marvelon to be effective and acceptable in Thai women. Moreover compared to Caucasian women, the incidences of irregular bleeding and side effects were apparently lower in these Asian women . Although Marvelon was used in many countries but it's efficacy didn't reported among Iranian women. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for desogestrel; ethinyl estradiol
Condition Name
Clinical Trial Locations for desogestrel; ethinyl estradiol
Trials by Country
Clinical Trial Progress for desogestrel; ethinyl estradiol
Clinical Trial Phase
Clinical Trial Sponsors for desogestrel; ethinyl estradiol
Sponsor Name
| Sponsor Name for desogestrel; ethinyl estradiol | |
| Sponsor | Trials |
| Oregon Clinical and Translational Research Institute | 1 |
| Oregon Health and Science University | 1 |
| Tehran University of Medical Sciences | 1 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
